Title : Resting blood BDNF in individuals with sickle cell disease and osteonecrosis
Abstract:
Introduction: Osteonecrosis is one of the most common musculoskeletal complications in sickle cell disease, which is a prevalent and particularly debilitating disorder in this population. Several studies have shown the relevance of brain-derived neurotrophic factor (BDNF) as a biomarker in various diseases including sickle cell disease.
Objective: This study aimed to measure of BDNF levels in individuals with sickle cell disease and osteonecrosis and compare them with healthy individuals.
Methods: This is an observational, cross-sectional study. The patient sample consisted of 18 individuals with sickle cell disease and osteonecrosis of the hip, and 8 individuals formed the control group. BDNF levels were determined by the ELISA technique. Statistical analyzes were performed using the SPSS program (version 25.0).
Results: The median and interquartile values of plasma BDNF levels in the control group were 302,38 pg/mL (IQR = 253,48 – 378,82), while in the patient group it was 1.189,85 pg/mL (IQR = 652,44 – 1.922,86).
Conclusions: These altered levels of BDNF may be one of the main features for the maintenance of chronic pain in individuals with sickle cell disease and may help to understand the mechanisms underlying central sensitization, a maladaptive phenomenon in the brain that could possibly be present in this population.
Keywords: Osteonecrosis. Sickle Cell Diseases. BDNF. Chronic Pain.